Preclinical pharmacokinetic studies of villocarine A, an active Uncaria alkaloid
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Yi-Hua Chiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Uncaria, Indole Alkaloids, Alkaloids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: UF College of Pharmacy, Ministry of Higher Education Malaysia.
Abstract (Originalsprache)
Villocarine A is a bioactive indole alkaloid isolated from the Uncaria genus. It has demonstrated vasorelaxation activity and potential to protect the central nervous system. To identify the pharmacokinetic properties of villocarine A, a series of in vitro and in vivo studies have been performed. Villocarine A was found to be highly permeable (15.6 ± 1.6*10 −6 cm/s) across human colorectal adenocarcinoma cell monolayer with high protein binding (>91%) in both rat and human plasma. Hepatic extraction ratio of villocarine A was 0.1 in pooled rat liver and 0.2 in human liver microsomes and was found stable in rat plasma at 37°C. Due to the high permeability and low rate of metabolism properties, villocarine A was initially considered suitable for preclinical development and an ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method for quantification (linearity: 1–150 ng/ml) in rat plasma was developed and validated for in vivo studies. Essential pharmacokinetic parameters included the volume of distribution and clearance of villocarine A, which were found to be 100.3 ± 15.6 L/kg and 8.2 ± 1.1 L/h/kg, respectively, after intravenous administration in rats. Following oral dosing, villocarine A exhibited rapid absorption as the maximum plasma concentration (53.2 ± 10.4 ng/ml) occurred at 0.3 ± 0.1 h, post‐dose. The absolute oral bioavailability of villocarine A was 16.8 ± 0.1%. To our knowledge, this was the first pharmacokinetic study of villocarine A, which demonstrated the essential pharmacokinetic properties of villocarine A: large volume distribution, high clearance, and low oral bioavailability in rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Centre for Drug Research, Universiti Sains Malaysia, Gelugor, Penang, Malaysia.
- Translational Drug Development Core, Clinical and Translational Science Institute, University of Florida, Gainesville, Florida, USA.
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Michelle A Kuntz, Alexandria S Senetra
Förderung
- UF College of Pharmacy
- Ministry of Higher Education Malaysia
Zitieren
APA
Chiang, Y. H., Chear, N. J., Berthold, E. C., Kuntz, M. A., Kanumuri, S. R. R., Senetra, A. S., Ramanathan, S., McCurdy, C. R., & Sharma, A. (2025). Preclinical pharmacokinetic studies of villocarine A, an active Uncaria alkaloid. Drug Testing and Analysis. https://doi.org/10.1002/dta.3703
Vancouver
Chiang YH, Chear NJ, Berthold EC, Kuntz MA, Kanumuri SRR, Senetra AS, et al. Preclinical pharmacokinetic studies of villocarine A, an active Uncaria alkaloid. Drug Testing and Analysis. 2025. doi:10.1002/dta.3703
BibTeX
@article{Chiang2025,
author = {Chiang, Yi-Hua and Chear, Nelson Jeng-Yeou and Berthold, Erin C and Kuntz, Michelle A and Kanumuri, Siva Rama Raju and Senetra, Alexandria S and Ramanathan, Surash and McCurdy, Christopher R and Sharma, Abhisheak},
title = {Preclinical pharmacokinetic studies of villocarine A, an active Uncaria alkaloid},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3703}
}
EUVIMED